Growth Opportunities in the Immuno-oncology Therapeutics Market, 2024–2030
Description
Worldwide cancer incidence is expected to exceed 35 million new cases by 2050, a 77% rise from the 20 million cases in 2022. Alcohol intake, tobacco usage, obesity, and air pollution are the main causes of this increase. Cancer studies today emphasize cell and gene therapy, antibody-drug conjugates (ADCs), checkpoint inhibitors, and multi-specific antibodies. With clinical trials emphasizing combinations of radiation, chemotherapy, or many immunotherapy medicines, more than 5,000 immuno-oncology medications are under development.
Although immuno-oncology (I-O) has revolutionized cancer therapy, problems with clinical trials must be resolved to improve patient outcomes and speed approvals. Many I-O therapies show failure when evaluated across too-large or incompatible patient groups; human immune responses cannot always be deduced from animal models and two-dimensional in vitro systems. Conventional randomized controlled studies may not find signs or call for continuous changes should a medicine not be functioning as expected.
AI and biomarker-based patient selection, combination approaches to offset resistance, real-time safety monitoring for immune-related adverse events, distributed clinical trials to improve patient access, and adaptive, AI-driven trial designs are fundamental strategies to meet these challenges. With these approaches, stakeholders are strengthening I-O innovation and improving the effectiveness, accessibility, and safety criteria of cancer therapy.
Improved biomarker platforms help to increase tumor immunobiology’s depth of knowledge and accuracy. Fast-growing fields in biomarker research include multiplex IHC, NGS-based testing for gene mutations and expression profiles, epigenetic mapping for higher-order gene structures, and metabolic profiling for tumor energy status.
Frost & Sullivan studied clinical and pipeline developments, technological innovation, and regional market dynamics to develop this research service, which provides an overview of the global I-O market and a revenue projection from 2025 to 2030. The geographical scope is North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America.
With an eye on checkpoint inhibitors, ADC, bispecific antibodies, cancer vaccines, and adoptive cell treatments including CAR-T, TCR, and TILs, this report examines the main themes and technologies driving the evolution of I-O therapies. Along with strategic target areas including overcoming resistance to PD-1/PD-L1 inhibitors, it stresses next-generation drugs including allogeneic approaches and multi-specific modalities. In this fast-changing environment, the study also investigates growth drivers, restraints, and opportunities for stakeholders.
Although immuno-oncology (I-O) has revolutionized cancer therapy, problems with clinical trials must be resolved to improve patient outcomes and speed approvals. Many I-O therapies show failure when evaluated across too-large or incompatible patient groups; human immune responses cannot always be deduced from animal models and two-dimensional in vitro systems. Conventional randomized controlled studies may not find signs or call for continuous changes should a medicine not be functioning as expected.
AI and biomarker-based patient selection, combination approaches to offset resistance, real-time safety monitoring for immune-related adverse events, distributed clinical trials to improve patient access, and adaptive, AI-driven trial designs are fundamental strategies to meet these challenges. With these approaches, stakeholders are strengthening I-O innovation and improving the effectiveness, accessibility, and safety criteria of cancer therapy.
Improved biomarker platforms help to increase tumor immunobiology’s depth of knowledge and accuracy. Fast-growing fields in biomarker research include multiplex IHC, NGS-based testing for gene mutations and expression profiles, epigenetic mapping for higher-order gene structures, and metabolic profiling for tumor energy status.
Frost & Sullivan studied clinical and pipeline developments, technological innovation, and regional market dynamics to develop this research service, which provides an overview of the global I-O market and a revenue projection from 2025 to 2030. The geographical scope is North America, Europe, Asia-Pacific, the Middle East and North Africa, and Latin America.
With an eye on checkpoint inhibitors, ADC, bispecific antibodies, cancer vaccines, and adoptive cell treatments including CAR-T, TCR, and TILs, this report examines the main themes and technologies driving the evolution of I-O therapies. Along with strategic target areas including overcoming resistance to PD-1/PD-L1 inhibitors, it stresses next-generation drugs including allogeneic approaches and multi-specific modalities. In this fast-changing environment, the study also investigates growth drivers, restraints, and opportunities for stakeholders.
Table of Contents
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
